The New AI Baseline… and How Sponsors Build an Advantage

By Nick Spittal, Chief Operations Officer, Velocity Clinical Research How many times have you heard the term AI this week? Sponsors are investing in it, CROs are building for it, and tech vendors are popping up left, right, and center to sell it. Sites are fully in the crosshairs, with hundreds of hours of procurement … Read more

What It Actually Means to Be a Partner in Clinical Research

By Andrew Reina, Chief Revenue Officer I spent the better part of two decades on the CRO side of clinical research, which gives you a particular vantage point. You see how sponsors evaluate site networks, what they ask for, and (more tellingly) what they don’t. Historically, this is a transactional relationship; a site’s job is … Read more

An Interview with William Beacham, MD on 40 Years of Practice, a Serendipitous Entry into Research, and the Future of Women’s Health Trials

There is a phrase William Beacham, MD reaches for when people ask how he ended up an OB-GYN: congenital gynecologist. It was his father’s speciality, too, and his grandfather was a physician. Four of his father’s five brothers also went into medicine. So, by the time Dr. Beacham was making his own choices, there was … Read more

61 FDA-Approved Products. One Global Network Behind Them.

A background image of part of the Earth from space, a circular image of a pill bottle, and text that reads, "61 FDA-Approved Products. One Network Behind Them."

Since 2020, Velocity Clinical Research has supported trials that contributed to 61 FDA-approved products — and we couldn’t be more proud of what that represents. Those 61 FDA-approved products span an extraordinary range of therapeutic areas: cardiovascular disease, obesity and diabetes, Alzheimer’s disease, respiratory conditions including RSV and COVID-19, dermatology, liver disease, migraine, multiple sclerosis, … Read more

Kris Kowdley, MD Quoted in Zydus Therapeutics Announcement

An image of Kris Kowdley's quote in the Zydus Announcement.

Congratulations to Zydus Therapeutics on the US FDA granting Priority Review to their New Drug Application for saroglitazar for the treatment of Primary Biliary Cholangitis (PBC)! Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG — Velocity Principal Investigator and EPICS-III Study Investigator — was featured in the Zydus Therapeutics announcement highlighting the Phase 3 results of … Read more

Kris Kowldey, MD, Featured in Mirum Pharmaceuticals Announcement of Phase 2b Study

Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, was featured in the recent Mirum Pharmaceuticals announcement that the VISTAS Phase 2b study of volixibat met its primary endpoint in patients with primary sclerosing cholangitis (PSC) and cholestatic pruritus. PSC is a rare, chronic liver disease with significant symptom burden and no approved therapies. In the VISTAS … Read more

Council on AI: New Framework Announcement

Advarra’s announcement of a new risk‑based AI governance framework features Raghu Punnamraju, CTO of Velocity Clinical Research, underscoring Velocity’s role in advancing responsible AI in clinical trials. Velocity is a founding member of the Council for Responsible Use of AI in Clinical Trials, a cross‑industry group convened by Advarra that brings together leaders from biopharma, … Read more

Clinical Trials Have a Representation Problem. This Site is Fixing It.

At Velocity Clinical Research Albuquerque, clinical research is being delivered in a way that reflects the community it serves. Led by Dr. Sara Friedman, a Principal Investigator with a background in OB/GYN, the Albuquerque site is a female-led team focused on women’s health and vaccines. Their work sits at the intersection of scientific rigor and … Read more